medi-cal no longer covering glp-1 California's Proposal to Cut Coverage for Medicare started covering GLP-1 weight

This backs customizing treatment plans to the individual

These global standards guide manufacturers in harmonising design and production processes across markets, focusing on compliance whilst maintaining product quality

OBES SURG 27(11):29332939 Noparatayaporn P, Thavorncharoensap M, Chaikledkaew U, Bagepally BS, Thakkinstian A (2021) Incremental net monetary benefit of bariatric surgery: systematic review and meta-analysis of cost-effectiveness evidences

Directing patients to these resources increases medication affordability and helps them stay on treatment, which improves your clinical outcomes and patient retention

Real-world studies have confirmed these results: a 2025 study published in Diabetes, Obesity and Metabolism found tirzepatide was associated with greater weight loss over 6 months than semaglutide in patients without diabetes, consistent with the trial data

The direct GLP-1 evidence in humans is still emerging, but the broader metabolic data is solid